Cytogen v. DuPont Merck
Cytogen sues DuPont Merck in New Jersey court for failure to fulfill its obligations to market Cytogen's cancer bone pain relief product Quadramet, Princeton-based Cytogen announces May 22. DuPont Merck had notified Cytogen that it would cease marketing Quadramet on May 25. According to Cytogen, DuPont Merck alleged that Cytogen "breached the license agreement" between the two companies, under which DuPont Merck had U.S. manufacturing and marketing responsibility while Cytogen was responsible for regulatory approvals and clinical development. DuPont Merck recently announced the dissolution of the joint venture; DuPont will buy out Merck's 50% stake
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth